Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic PLD in primary endocrine resistant advanced breast cancer
NCT03071926Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Mar 2017
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of doxorubicin in breast cancer, sponsored by Fudan University. Status: unknown.
02
Drugs
doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03071926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071926.